Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
In: European Journal of Haematology, Jg. 82 (2009-06-01), S. 458-465
Online
unknown
Zugriff:
Objective: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20–30 mg/kg/d reduces iron burden, depending on transfusional iron intake. Methods: The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients ≥2 yr with β-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone. Most patients began treatment with deferasirox 20 mg/kg/d; doses were adjusted in response to markers of over- or under-chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of ≥3 mg Fe/g dry weight (dw) if baseline LIC was ≥10 mg Fe/g dw, or final LIC of 1–7 mg Fe/g dw for patients with baseline LIC of 2 to
Titel: |
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
|
---|---|
Autor/in / Beteiligte Person: | El-Beshlawy, Amal ; Kriemler-Krahn, Ulrike ; Taher, Ali T. ; Daar, Shahina ; Kusai Al Zir ; Habr, Dany ; Abdullah Al Jefri ; Hmissi, Abdel ; Mohsen Saleh Elalfy |
Link: | |
Zeitschrift: | European Journal of Haematology, Jg. 82 (2009-06-01), S. 458-465 |
Veröffentlichung: | Wiley, 2009 |
Medientyp: | unknown |
ISSN: | 1600-0609 (print) ; 0902-4441 (print) |
DOI: | 10.1111/j.1600-0609.2009.01228.x |
Schlagwort: |
|
Sonstiges: |
|